Slingluff CL - Search Results

1

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling.

Meneveau MO, Kumar P, Lynch KT, Patel SP, Slingluff CL. Meneveau MO, et al. Among authors: slingluff cl. J Immunother Cancer. 2022 Mar;10(3):e003533. doi: 10.1136/jitc-2021-003533. J Immunother Cancer. 2022. PMID: 35277457 Free PMC article.

2

Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms.

Slingluff CL. Slingluff CL. Cancer Immunol Immunother. 1999 Oct;48(7):371-3. doi: 10.1007/s002620050588. Cancer Immunol Immunother. 1999. PMID: 10501849 Free PMC article. Review.

3

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH. Slingluff CL Jr, et al. Cancer Immunol Immunother. 2000 Mar;48(12):661-72. doi: 10.1007/s002620050015. Cancer Immunol Immunother. 2000. PMID: 10752474 Free PMC article.

4

Vaccination for melanoma.

Thompson LW, Brinckerhoff L, Slingluff CL Jr. Thompson LW, et al. Among authors: slingluff cl jr. Curr Oncol Rep. 2000 Jul;2(4):292-9. doi: 10.1007/s11912-000-0021-0. Curr Oncol Rep. 2000. PMID: 11122856 Review.

5

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff CL Jr. Yamshchikov GV, et al. Among authors: slingluff cl jr. Int J Cancer. 2001 Jun 1;92(5):703-11. doi: 10.1002/1097-0215(20010601)92:5<703::aid-ijc1250>3.0.co;2-5. Int J Cancer. 2001. PMID: 11340576

6

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG. Slingluff CL Jr, et al. Clin Cancer Res. 2001 Oct;7(10):3012-24. Clin Cancer Res. 2001. PMID: 11595689 Clinical Trial.

7

Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine.

Woodson EM, Chianese-Bullock KA, Wiernasz CJ, Bissonette EA, Grosh WW, Neese PY, Merrill PK, Barnd DL, Petroni GR, Slingluff CL Jr. Woodson EM, et al. Among authors: slingluff cl jr. J Immunother. 2004 Sep-Oct;27(5):380-8. doi: 10.1097/00002371-200409000-00006. J Immunother. 2004. PMID: 15314546 Clinical Trial.

8

Competition among peptides in melanoma vaccines for binding to MHC molecules.

Thompson LW, Garbee CF, Hibbitts S, Brinckerhoff LH, Pierce RA, Chianese-Bullock KA, Deacon DH, Engelhard VH, Slingluff CL Jr. Thompson LW, et al. Among authors: slingluff cl jr. J Immunother. 2004 Nov-Dec;27(6):425-31. doi: 10.1097/00002371-200411000-00002. J Immunother. 2004. PMID: 15534486

9

MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.

Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW, Merrill P, Fink R, Woodson EM, Wiernasz CJ, Patterson JW, Slingluff CL Jr. Chianese-Bullock KA, et al. Among authors: slingluff cl jr. J Immunol. 2005 Mar 1;174(5):3080-6. doi: 10.4049/jimmunol.174.5.3080. J Immunol. 2005. PMID: 15728523

10

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.

Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK. Slingluff CL Jr, et al. Clin Cancer Res. 2007 Nov 1;13(21):6386-95. doi: 10.1158/1078-0432.CCR-07-0486. Clin Cancer Res. 2007. PMID: 17975151 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

276 results

Search Page

Filters